What can we help you find?
A Pioneering Study Discovers an Underlying Cause for Infantile Spasms and Points to a Novel Therapy
ResearchFeaturing the research of former CURE Epilepsy grantee Dr. John Swann. This exciting study, published in the Annals of Neurology, has the potential to transform the treatment landscape for babies with infantile spasms.Insights Into Genes Driving Epilepsy Could Help With Treatment
ResearchDanish researchers have found genetic causes for epilepsy in half of children they studied and said half of those could be treated with targeted therapies.Effects of Double-Dose Statin Therapy for the Prevention of Post-Stroke Epilepsy: A Prospective Clinical Study
ResearchIncreasing the dose of statin treatment during the acute phase of ischemic stroke reduces the incidence of post-stroke epilepsy.FDA Approves New Therapy for Dravet Syndrome
ResearchThe FDA has approved Fintepla® (fenfluramine) for the treatment of seizures associated with Dravet syndrome in patients age 2 and older.New Therapy Stops Seizures in Mouse Model of Rare Childhood Epilepsy
ResearchSCN8A encephalopathy could be improved with a treatment already approved for other uses.
Pilot Study Suggests Sleep Monitoring Alone, With or Without Cognitive Behavioral Therapy, May Improve Sleep Quality and Quality of Life for People with Epilepsy
ResearchThe treatment and control groups improved on measures of sleep quality, quality of life, sleep hygiene behaviors, and dysfunctional beliefs about sleep.NeuCyte to Advance Novel Compound for Treatment of Refractory Epilepsy and Related Neurological Disorders
ResearchThe compound covered by this agreement has demonstrated highly encouraging activity during studies conducted by the NINDS Epilepsy Therapy Screening Program ETSP.Therapy That Targets Underlying Cause of Dravet Syndrome Gets Orphan Drug Status
ResearchThe FDA has granted Orphan Drug designation to STK-001 (Stoke Therapeutics) for the treatment of Dravet syndrome.